A
Azanta
Markets and distributes pharmaceutical products
About Azanta
Azanta A/S, now a wholly owned subsidiary of Norgine B.V., operates in the pharmaceutical industry, focusing on specialized healthcare solutions. The company serves a diverse range of clients, including healthcare professionals and institutions, primarily in the fields of obstetrics, mucosal protection, and addiction medicine. Azanta's market presence spans across Europe, Australia, and New Zealand, leveraging Norgine's extensive distribution network to bring its products to market effectively. The business model revolves around the development, acquisition, and distribution of niche pharmaceutical products. Revenue is generated through the sales of these specialized medications, which address specific medical needs that are often underserved by larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Founded
- 1994
- Headquarters
- Copenhagen, Denmark
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Norgine Ventures- EPEuropean Equity Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Azanta on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Azanta on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.